跳至主要内容
临床试验/CTRI/2013/06/003761
CTRI/2013/06/003761招募中4 期

An Observational, Multicentre, Prospective, Post Marketing Surveillance study to evaluate safety and efficacy of ELORESTM (Ceftriaxone, Sulbactam and Disodium Edetate) in patients with various bacterial infections (Labeled indications).

Venus Remedies Limited0 个研究点目标入组 2,500 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
入组人数
2,500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Pms

入排标准

入选标准

  • Eligibility Criteria:
  • 1. Patients with a suspected or confirmed diagnosis of bacterial infection (labelled indications)
  • 2. Patients who receive a prescription of ELORES according to the indication stated in the local
  • approved SmPC [Lower Respiratory Tract Infections, Urinary Tract Infections (complicated and
  • uncomplicated), Bacterial Septicaemia, Chronic Suppurative Otitis Media, Infections of Bones
  • and Joints, Infections of Skin and Soft Tissues, Surgical Prophylaxis (including pre and postsurgical
  • infections)]
  • 3. Written informed consent signed by the patient or legally acceptable representative(s) in line
  • with applicable regulation of country.
  • 4. Planned treatment in line with the Summary of Product Characteristics, i.e. exclusion of all
  • patients with contraindications.

排除标准

  • No Exclusion criteria in view of Non-Interventional Observational PMS study.

研究者

相似试验